Back to News
Market Impact: 0.45
Viking's VK2735 Shows Strong Weight-Loss Maintenance With Less Frequent Dosing; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Viking Therapeutics reported positive topline maintenance-study results for obesity candidate VK2735. Patients maintained most of their weight loss after transitioning from weekly administration to less frequent dosing, supporting the drug's potential convenience and long-term treatment profile.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
VKTX0.82
More News
- Viking Therapeutics shares surge over 27% on weight loss drug maintenance data
- Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
- Alibaba Higher on Chip News; On Holdings Football Move | Stock Movers
- Trump Says US Team Met With Iranians at UNGA
- Heidi CEO on AI in Healthcare, $900M valuation
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant